Fresh analysis indicates that people who come off blockbuster slimming jabs like semaglutide or tirzepatide can put back on reduced body mass far faster than those who halt conventional lifestyle regimens.
Research printed in a major health publication demonstrates that while overweight people can lose a large proportion of their total mass while using the jabs, the weight returns at an estimated rate of 0.8 kg per month upon discontinuation.
"People buying such treatments need to be aware of the risk of quick rebound weight gain when the medication is stopped," stated expert Dr. Susan Jebb.
Such speed of recovery implies a reversion to original weight within about a year and a half.
Weighing Approaches
The study, which examined 37 of trials involving over 9,000 of participants, contrasted the outcomes of these new drugs with older methods.
Researchers point out that people who lose weight through lifestyle changes alone generally see a slower creep back—around 100 grams monthly—after stopping.
The Reason for the Quick Regain
Experts suggest the mode of action of the injections is key to understanding the amplified weight return.
The injections imitate a body's own chemical called glucagon-like peptide-1, which helps regulate appetite.
"Long-term administration of the hormone levels far above than normal might result in the system to generate a reduced amount of its endogenous hormone, and could diminish responsiveness to its effects," explained Dr. Adam Collins, a nutrition specialist.
"Withdrawal of this GLP-1 'fix' results in hunger is uncontrolled, making binge eating a significant risk."
A Lifelong Condition?
Health authorities recommend the jabs for people with obesity-related health risks, accompanied by recommended lifestyle changes.
A number of clinicians contend that, given the high risk of weight regain, the treatment should be considered long-term.
This perspective is echoed by pharmaceutical companies, who say that the findings "highlight the long-term nature of obesity," comparing it to managing conditions like hypertension.
Patient Experiences
Users who have discontinued the medication describe a powerful resurgence of hunger.
"I experienced a switch activating and you become ravenous," said one woman.
This challenge is worsened if patients have not established sustainable lifestyle or habit changes during treatment.
Widespread Adoption
Survey data indicate that millions of people in the UK have tried these injections in the past year, with desire being substantial.
- Adoption is higher among women compared to men.
- The middle-aged age group shows the greatest usage rates.
- A large proportion obtain the medications through private healthcare rather than public health services.
In conclusion, clinicians caution that while the jabs are potent agents for weight loss, they are not a magic solution and long-term success hinges on ongoing lifestyle changes.
